Author:
Rupniak Nadia M.J.,Kramer Mark S.
Subject
Psychiatry and Mental health,Clinical Psychology
Reference35 articles.
1. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant;Barrett;Curr. HIV Res.,2014
2. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?;Barrett;J. Clin. Psychopharmacol.,2013
3. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant;Bergstrom;Biol. Psychiatry,2004
4. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity;Conley;J. Neurosci.,2002
5. Chappell, P., 2002. Effects of CP-122,721, A Selective NK1 Receptor Antagonist, in Patients with MDD. Presented at NCDEU, June12.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献